ARTICLE | Company News
NewLink, Merck, U.S. Department of Health and Human Services infectious news
October 10, 2016 7:00 AM UTC
HHS’s Biomedical Advanced Research and Development Authority (BARDA) granted NewLink’s BioProtection Systems subsidiary a contract worth up to $75.8 million to develop rVSV-ZEBOV-GP Ebola vaccine. BioProtection will receive initial funding of $24.8 million. The contract includes options for an additional $51 million. The funding will support manufacturing and additional clinical trials. In 2014, BARDA awarded NewLink a separate contract to develop the vaccine. ...